| Literature DB >> 32743363 |
Atsuhiko Ochi1, Bo Fan1, Natsuo Kimura1, Hisaki Watanabe1, Sari Toki1, Wataru Fukuokaya1, Daigo Okada1, Koichi Aikawa1, Tingwen Huang1, Koichiro Suzuki1, Naoki Shiga1, Yasuhide Kitagawa2, Hirokazu Abe1.
Abstract
INTRODUCTION: Surgical manipulation of a pheochromocytoma carries the risk of releasing catecholamines into bloodstream leading to severe intraoperative hypertension. CASEEntities:
Keywords: adrenal artery; adrenal vein; catecholamine; giant pheochromocytoma; open adrenalectomy
Year: 2018 PMID: 32743363 PMCID: PMC7292064 DOI: 10.1002/iju5.12027
Source DB: PubMed Journal: IJU Case Rep ISSN: 2577-171X
Patient characteristics
| Variables | Case 1 | Case 2 | Case 3 |
|---|---|---|---|
| Age (years) | 40 | 63 | 66 |
| Sex | Female | Male | Female |
| Body mass index (kg/m2) | 24.9 | 25.1 | 22.7 |
| Preoperative hypertension | Absent | Present | Absent |
| Tumor size (cm) | 10.4 × 8.8 | 10.2 × 8.2 | 11.0 × 7.0 |
| Preoperative urinary catecholamines | |||
| Epinephrine (μg/day) | 26.6 | 10.1 | 9.5 |
| Norepinephrine (μg/day) | 374.5 | 378.6 | 124.5 |
| Dopamine (μg/day) | 675.1 | 1355.7 | 58635.0 |
| Metanephrine (mg/day) | 0.96 | 0.23 | 0.17 |
| Normetanephrine (mg/day) | 13.2 | 11.7 | 0.26 |
| Uptake on 123I‐MIBG scintigraphy | Present | Present | Present |
| Preoperative medication: doxazosin (mg/day) | 16 | 16 | 16 |
Figure 1Enhanced CT scan showing the AAs behind the IVC (red arrows).
Figure 2(a) The connective tissue contained the right AAs from the VA. (b) The schema of right AA ligation between the IVC and the VA (black arrow). (c) The schema of right AA ligation between the tumor and the upper pole of the right kidney (black arrow). The right kidney was pulled to the caudal side (green arrow).
Surgical and postoperative outcomes
| Variables | Case 1 | Case 2 | Case 3 |
|---|---|---|---|
| Operative time (minutes) | 297 | 268 | 180 |
| Estimated blood loss (mL) | 390 | 600 | 230 |
| Blood transfusion (mL) | None | None | 280 |
| Maximal systolic blood pressure (mmHg) | 150 | 140 | 150 |
| Perioperative complications | None | None | None |
| Follow‐up period (months) | 49 | 50 | 33 |
| Tumor recurrence | None | None | None |